J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's drug https://ift.tt/stYSRfK

J&J said on Thursday it expects the combination to become a first-line treatment for non small-cell lung cancer (NSCLC) patients with a type of mutation in EGFR protein that causes rapid tumor cell growth.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/0g6IwmF